Dendritic Cell Therapy: A New Immunotherapy Approach to Cancer Treatment — How It Works and What You Should Know

Dendritic Cell Therapy is one of the personalized immunotherapy approaches used as an alternative or complementary option in cancer care. It was developed based on the properties of Dendritic Cells, immune cells that naturally occur in the body.

An important function of Dendritic Cells is to detect foreign substances, pathogens, and abnormal cells such as cancer cells. They then process and present fragments of these substances, known as antigens, to T-cells in order to stimulate an appropriate immune response.

Based on this principle, Dendritic Cell Therapy has been developed as a complementary approach for certain cancer patients. Monocytes, a type of white blood cell, are collected from the patient and cultured in a standardized laboratory to develop into Dendritic Cells. These cells are then exposed to cancer-cell antigens (Tumor Antigens) and stimulated to reach the mature stage (Maturation) before being administered back into the patient's body using an appropriate method.

The Dendritic Cells then present the cancer antigens to T-cells, particularly CD8+ T-cells (Cytotoxic T lymphocytes), which play an important role in recognizing and eliminating cancer cells.

After Dendritic Cells are administered back into the body, they migrate to the lymph nodes and present cancer-cell antigens to T-cells, stimulating an immune response.

Activated T-cells then multiply and travel to areas containing cancerous or abnormal cells. When they detect the target antigen on the surface of cancer cells, the T-cells bind to those cells and release important substances such as Perforin and Granzyme, triggering the cancer cells to undergo natural programmed cell death (Apoptosis).

However, Dendritic Cell Therapy does not directly destroy cancer cells in the same way as chemotherapy or radiation therapy. Instead, it supports the body's immune system in recognizing and responding more specifically to cancer cells.

For this reason, it is often considered as a complementary approach used alongside standard cancer treatment under the supervision and assessment of a qualified physician.

Treatment outcomes may vary between patients depending on several factors, including the type of cancer, stage of disease, the antigen used, and the individual patient's immune response.

May help T-cells recognize cancer cells more effectively: Dendritic Cells present cancer-cell antigens to T-cells, particularly CD8+ T-cells, which are involved in detecting and eliminating abnormal cells. This is consistent with a 2025 review stating that Dendritic Cells play an important role in activating anti-cancer immunity and may help the body recognize and respond more specifically to cancer-cell targets. However, this therapy does not provide guaranteed results for every patient and still has limitations that require further development and research (Sheykhhasan et al., 2025).

May support disease control or slow progression in some cases: When T-cells are better able to recognize cancer-cell antigens, the immune system may continuously detect and respond to cancer cells. This may contribute to disease control in some patients, although outcomes depend on multiple factors. A 2025 study involving 16 patients with pancreatic cancer following surgery who received a Neo-P DC vaccine, a Dendritic Cell vaccine stimulated with neoantigen peptides, found that cancer antigen-specific T-cell responses were generated in 13 patients, or 81.3%. Patients who developed T-cell responses also tended to have better clinical outcomes. However, this was a retrospective study with a limited number of patients (Oyama et al., 2025).

May enhance treatment when combined with standard cancer therapies: These may include chemotherapy, radiotherapy, targeted therapy, and other forms of immunotherapy. Research in patients with esophageal cancer found that combining a Dendritic Cell Vaccine with radiotherapy could stimulate a cancer-specific immune response. However, the study was observational and included a limited number of patients (Wang et al., 2017).

A meta-analysis compiling data from four studies involving 871 patients with colorectal cancer found that chemotherapy combined with a Dendritic Cell Vaccine and CIK Cell Therapy was associated with better survival outcomes than chemotherapy alone. However, the evidence has limitations because it included only four studies and could not clearly separate the effects of the Dendritic Cell Vaccine from those of CIK Cell Therapy (Zhou et al., 2018).

Dendritic Cell Therapy is currently being studied as a complementary approach for several types of cancer, including:

• Prostate Cancer
• Glioblastoma (GBM)
• Melanoma
• Renal Cell Carcinoma (RCC)
• Other solid tumors, such as lung cancer, breast cancer, colorectal cancer, pancreatic cancer, and certain types of ovarian cancer, which continue to be investigated
• Certain hematologic cancers, such as Multiple Myeloma, Acute Myeloid Leukemia (AML), and some types of Lymphoma, most of which remain under study or clinical investigation

However, suitability and treatment outcomes can vary between individuals depending on several factors, including cancer type and stage, overall physical condition, immune-system response, and other treatments being used.

Patients should therefore consult a physician for an individualized assessment before deciding to undergo treatment.

It is also important to understand that Dendritic Cell Therapy is a complementary approach intended to support immune-system function and cannot replace standard medical cancer treatment.

Although Dendritic Cell Therapy has been developed as a complementary treatment option for certain types of cancer, it may not be suitable for some patients, including:

• Patients with immune-system disorders or severe immunodeficiency, as immune stimulation may worsen certain conditions in some individuals
• Patients with an acute infection, fever, or severe inflammation
• Patients with severe uncontrolled underlying conditions, such as heart, liver, kidney, or lung disease
• Patients who are extremely physically debilitated and unable to undergo treatment continuously
• Patients who are pregnant or breastfeeding, as there is currently insufficient safety information
• Patients with unrealistic expectations who intend to use Dendritic Cell Therapy as a replacement for standard cancer treatment

In general, Dendritic Cell Therapy is an immunotherapy-based cancer treatment process that may be carried out appropriately and safely when performed under close supervision by a qualified physician in a standardized medical facility or treatment center.

However, because the treatment involves stimulation of the immune system, temporary side effects may occur, including:

• Pain, swelling, redness, or irritation at the cell injection site
• Mild fever or chills
• Fatigue or headache
• Muscle and joint aches
• Nausea, loss of appetite, or temporary abdominal discomfort

Dendritic Cell Therapy is one of the immunotherapy approaches that has been studied and applied in patients with several types of cancer. However, there are important limitations that should be understood before treatment:

• It cannot replace standard treatment. Dendritic Cell Therapy is generally considered a complementary approach that may be used alongside standard cancer treatment at the physician's discretion.
• It cannot be used for every type of cancer. Further studies are still required to confirm its effectiveness and suitability in certain groups of cancer patients.
• Results vary between individuals. Some patients may respond well, while others may require more time before changes are observed or may experience limited effects. Outcomes depend on several factors, such as the type and stage of cancer, the antigen used, the tumor microenvironment, and the patient's immune-system response.
• Treatment may take several weeks. The process involves cell collection, cell separation, cell culture, antigen stimulation, and repeated cell administration according to a treatment schedule established by the physician.
• The cost can be relatively high. This is because the treatment requires advanced technology to prepare individualized cells and requires supervision by a specialized medical team.

Proper self-care before and after Dendritic Cell Therapy is important to help ensure that the body is in suitable condition and to reduce the risk of possible side effects.

Self-Care Before Dendritic Cell Therapy

• Visit the physician for a detailed health assessment. Blood tests may be performed to evaluate blood-cell status, immune-system function, and the function of major organs. The physician may also assess the type and stage of cancer and previous treatment history to develop an appropriate treatment plan.
• Inform the physician in detail about underlying medical conditions, current medications, supplements, herbal products, and any history of drug allergies.
• Get adequate rest to prepare the body before cell collection.
• Eat nutritious foods and drink sufficient clean water.
• Avoid using certain medications, supplements, or herbal products without consulting the physician.
• If you develop a fever, infection, or acute illness, inform the physician so that the appointment can be postponed until you have recovered.

Self-Care After Dendritic Cell Therapy

• Drink more water, or follow the amount recommended by the physician, and get adequate rest.
• Avoid crowded places and close contact with sick individuals to reduce the risk of infection.
• Maintain good hygiene, wash your hands frequently, and regularly check your body temperature.
• Eat nutritious, freshly prepared foods to support immune-system balance.
• Avoid strenuous exercise or activities that cause excessive fatigue during the early treatment period.
• Attend all scheduled medical follow-ups so the physician can monitor symptoms and the body's response. Avoid missing or postponing appointments unnecessarily.
• Continuously monitor your condition. If abnormal symptoms occur, such as a high fever lasting more than 48 hours, difficulty breathing, chest tightness, progressively worsening pain at the injection site, a severe allergic reaction, unusual weakness, or decreased alertness, seek medical attention immediately.